Budget Amount *help |
¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2018: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
Outline of Final Research Achievements |
New therapy for angiosarcoma is urgent because there are few effective treatments. Heat shock protein 90 (HSP90) regulates cancer-associated proteins and many clinical trials of HSP90 inhibitors are on-going in several cancers. In this study, we investigated the anti-tumor effect of HSP90 inhibition. HSP90 protein are overexpressed in angiosarcoma patient’s tissues and cell lines. Knockdown of HSP90 inhibited the proliferation/migration/invasion of angiosarcoma cells. These anti-tumor effect were based on the suppression of several downstream targets of VEGF signaling. Taken together, HSP90 is a novel therapeutic target against angiosarcoma.
|